rheumatology

Oral JAK inhibitor more effective than placebo or adalimumab: RA-BEAM

The oral Janus kinase (JAK) inhibitor baricitinib is more effective than placebo or adalimumab (Humira) among RA patients with an inadequate response to methotrexate, a phase III trial shows. Results from the double-blind placebo and active controlled RA-BEAM study published in this week’s New England Journal of Medicine revealed that the trial’s primary efficacy end ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic